{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:29:41Z","timestamp":1793690981043,"version":"4.5.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"DOI":"10.7759\/cureus.85957","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T21:09:05Z","timestamp":1749848945000},"source":"Crossref","is-referenced-by-count":1,"title":["Rapid Onset of Fulminant Type 1 Diabetes 10 Days After the First Dose of Nivolumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Yoshinori","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Tateyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright JJ","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021, 17:389-99. 10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk HK","year":"2019","unstructured":"Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019, 36:1075-81. 10.1111\/dme.14050","journal-title":"Diabet Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14362","article-title":"Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association","volume":"16","author":"Kamitani F","year":"2025","unstructured":"Kamitani F, Nishioka Y, Koizumi M, et al.. Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association. J Diabetes Investig. 2025, 16:334-42. 10.1111\/jdi.14362","journal-title":"J Diabetes Investig"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden MY","year":"2019","unstructured":"Baden MY, Imagawa A, Abiru N, et al.. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019, 10:58-66. 10.1007\/s13340-018-0362-2","journal-title":"Diabetol Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1539-9","article-title":"Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset","volume":"52","author":"Kawabata Y","year":"2009","unstructured":"Kawabata Y, Ikegami H, Awata T, et al.. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009, 52:2513-21. 10.1007\/s00125-009-1539-9","journal-title":"Diabetologia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12024","article-title":"Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus","volume":"3","author":"Imagawa A","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T, et al.. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J Diabetes Investig. 2012, 3:536-9. 10.1111\/jdi.12024","journal-title":"J Diabetes Investig"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette JM","year":"2019","unstructured":"de Filette JM, Pen JJ, Decoster L, et al.. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019, 181:363-74. 10.1530\/EJE-19-0291","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes J","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015, 38:e55-7. 10.2337\/dc14-2349","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk HK","year":"2018","unstructured":"Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW. PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity. J Clin Endocrinol Metab. 2018, 103:3589-92. 10.1210\/jc.2018-01430","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci ML","year":"2017","unstructured":"Gauci ML, Laly P, Vidal-Trecan T, et al.. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother. 2017, 66:1399-410. 10.1007\/s00262-017-2033-8","journal-title":"Cancer Immunol Immunother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0351","article-title":"Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners","volume":"3","author":"Hanafusa T","year":"2007","unstructured":"Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007, 3:36-45; quiz 2p following 69. 10.1038\/ncpendmet0351","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2011.00139.x","article-title":"Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies","volume":"3","author":"Tsutsumi C","year":"2012","unstructured":"Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012, 3:62-9. 10.1111\/j.2040-1124.2011.00139.x","journal-title":"J Diabetes Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457213","article-title":"Fifty years of HLA-associated type 1 diabetes risk: history, current knowledge, and future directions","volume":"15","author":"Noble JA","year":"2024","unstructured":"Noble JA. Fifty years of HLA-associated type 1 diabetes risk: history, current knowledge, and future directions. Front Immunol. 2024, 15:1457213. 10.3389\/fimmu.2024.1457213","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type\u00a01 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto M","year":"2016","unstructured":"Okamoto M, Okamoto M, Gotoh K, et al.. Fulminant type\u00a01 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig. 2016, 7:915-8. 10.1111\/jdi.12531","journal-title":"J Diabetes Investig"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman K","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CE. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018, 103:3144-54. 10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal A","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019, 7:e000591. 10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: assessing toxicities, body composition\u00a0and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely JR Jr","year":"2020","unstructured":"Patrinely JR Jr, Young AC, Quach H, et al.. Survivorship in immune therapy: assessing toxicities, body composition\u00a0and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020, 135:211-20. 10.1016\/j.ejca.2020.05.005","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez E","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016, 21:804-16. 10.1634\/theoncologist.2015-0509","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370350-rapid-onset-of-fulminant-type-1-diabetes-10-days-after-the-first-dose-of-nivolumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:04:11Z","timestamp":1793689451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370350-rapid-onset-of-fulminant-type-1-diabetes-10-days-after-the-first-dose-of-nivolumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}